Circulating tumor DNA is a powerful tool for detecting systemic minimal residual disease but is not sensitive enough for local, non-muscle invasive recurrences. This limitation means traditional surveillance like cystoscopy remains indispensable, as a negative ctDNA test can provide a false sense of security about local control.

Contrary to assumption, persistent ctDNA after neoadjuvant therapy does not always mean incurable systemic disease. Surgery alone can clear the ctDNA in roughly half of these patients, suggesting the ctDNA source is often the resectable primary tumor, making cystectomy a potentially curative intervention.

Professor Powles highlights a critical limitation of ctDNA in bladder cancer management. While excellent for assessing systemic risk, ctDNA may remain negative during a local, non-muscle invasive relapse (e.g., T1 cancer). This necessitates continued local surveillance like cystoscopy, even in ctDNA-negative patients pursuing bladder-sparing approaches.

The future of bladder cancer surveillance may involve using two types of liquid biopsies in tandem. A patient who is utDNA-positive but ctDNA-negative likely has a local, primary bladder issue. Conversely, a utDNA-negative but ctDNA-positive result suggests the cancer has already spread systemically, providing crucial information for treatment planning.

Beyond a simple positive/negative result, the quantitative level of ctDNA is highly prognostic in bladder cancer. Similar to PSA in prostate cancer, higher ctDNA levels correlate with a significantly worse prognosis, offering a more nuanced risk assessment tool than a binary test.

A positive circulating tumor DNA (ctDNA) test in a patient with a known bladder tumor can be misinterpreted as metastatic disease. However, the local tumor itself sheds DNA. Resecting this tumor can clear the ctDNA signal, a critical nuance to prevent misdiagnosis and premature, aggressive systemic therapy.

Experts suggest urinary tumor DNA (utDNA) may better reflect local disease in the bladder, while circulating tumor DNA (ctDNA) indicates systemic disease. Using both tests in parallel could provide a more complete picture, with dual-negative results potentially becoming a key criterion for safely pursuing bladder-sparing approaches.

A positive ctDNA (blood) but negative utDNA (urine) test suggests systemic, metastatic disease. Conversely, a positive utDNA with negative ctDNA points to a tumor confined to the bladder. This integrated biomarker approach can help determine whether systemic therapy or local treatment like surgery is the priority.

Across multiple recent trials, a consistent finding is that if a bladder cancer patient's circulating tumor DNA (ctDNA) does not clear after treatment, it is an extremely poor prognostic sign. This strong signal suggests that these patients should likely be switched to a different therapeutic approach immediately.